PFE · Pfizer Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $62.58B | $63.63B | $91.79B | $41.65B | $81.29B | $41.91B |
| Cost of Revenue | $16.07B | $17.85B | $24.95B | $34.34B | $30.82B | $8.69B |
| Gross Profit | $46.51B | $45.78B | $66.84B | $7.31B | $50.47B | $33.22B |
| R&D | $10.44B | $10.82B | $10.68B | $11.43B | $13.83B | $9.40B |
| SG&A | $13.79B | $14.73B | $14.77B | $13.68B | $12.70B | $11.62B |
| Total Operating Expenses | - | - | - | - | - | - |
| D&A | $6.59B | $7.01B | $6.29B | $5.06B | $4.68B | - |
| Operating Income | $7.52B | $8.02B | $1.06B | $34.73B | $24.31B | $7.50B |
| Interest Expense | $2.67B | $3.09B | $2.21B | $1.24B | $1.29B | $1.45B |
| Income Tax | ($266.00M) | ($28.00M) | ($1.11B) | $3.33B | $1.85B | $477.00M |
| Net Income | $7.77B | $8.03B | $2.12B | $31.37B | $21.98B | $9.62B |
| EPS - Basic | $1.37 | $1.42 | $0.38 | $5.59 | $3.92 | $1.73 |
| EPS - Diluted | $1.36 | $1.41 | $0.37 | $5.47 | $3.85 | $1.71 |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.14B | $1.04B | $2.85B | $416.00M | $1.94B | $1.78B |
| Accounts Receivable | $11.87B | $11.46B | $11.18B | $10.95B | $11.48B | $7.93B |
| Inventory | $10.65B | $10.85B | $10.19B | $8.98B | $9.06B | $8.05B |
| Accounts Payable | $5.24B | $5.63B | $6.71B | $6.81B | $5.58B | $4.31B |
| Current Assets | $42.90B | $50.36B | $43.33B | $51.26B | $59.69B | $35.07B |
| Total Assets | $208.16B | $213.40B | $226.50B | $197.21B | $181.48B | $154.23B |
| Current Liabilities | $36.98B | $42.99B | $47.79B | $42.14B | $42.67B | $25.92B |
| Long-term Debt | $61.64B | $57.41B | $61.54B | $32.88B | $36.20B | $37.13B |
| Total Liabilities | $121.39B | $124.90B | $137.21B | $101.29B | $104.01B | $90.76B |
| Stockholders' Equity | $86.48B | $88.20B | $89.01B | $95.66B | $77.20B | $63.24B |
| Retained Earnings | $114.61B | $116.72B | $118.35B | $125.66B | $103.39B | $96.77B |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $11.70B | $12.74B | $8.70B | $29.27B | $32.58B | $14.40B |
| Investing Cash Flow | ($1.35B) | $2.65B | ($32.28B) | ($15.78B) | ($22.55B) | ($4.27B) |
| Financing Cash Flow | ($10.30B) | ($17.14B) | $26.07B | ($14.83B) | ($9.82B) | ($9.65B) |
| CapEx | $2.63B | $2.91B | $3.91B | $3.24B | $2.71B | $2.25B |
| Free Cash Flow | $9.07B | $9.84B | $4.79B | $26.03B | $29.87B | $12.15B |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 74.3% | 71.9% | 72.8% | 17.5% | 62.1% | 79.3% |
| Operating margin | 12.0% | 12.6% | 1.2% | 83.4% | 29.9% | 17.9% |
| EBITDA margin | 22.6% | 23.6% | 8.0% | 95.5% | 35.7% | - |
| Net margin | 12.4% | 12.6% | 2.3% | 75.3% | 27.0% | 22.9% |
| Free cash flow margin | 14.5% | 15.5% | 5.2% | 62.5% | 36.7% | 29.0% |
| FCF / Net income | 1.17 | 1.22 | 2.26 | 0.83 | 1.36 | 1.26 |
| R&D / Revenue | 16.7% | 17.0% | 11.6% | 27.4% | 17.0% | 22.4% |
| SG&A / Revenue | 22.0% | 23.2% | 16.1% | 32.8% | 15.6% | 27.7% |
| Effective tax rate | -3.5% | -0.3% | -111.1% | 9.6% | 7.8% | 4.7% |
| Return on assets | 3.7% | 3.8% | 0.9% | 15.9% | 12.1% | 6.2% |
| Return on equity | 9.0% | 9.1% | 2.4% | 32.8% | 28.5% | 15.2% |
| Return on invested capital | 5.1% | 5.5% | 0.7% | 24.4% | 19.8% | 7.1% |
| Liquidity | ||||||
| Current ratio | 1.16 | 1.17 | 0.91 | 1.22 | 1.40 | 1.35 |
| Quick ratio | 0.87 | 0.92 | 0.69 | 1.00 | 1.19 | 1.04 |
| Cash ratio | 0.03 | 0.02 | 0.06 | 0.01 | 0.05 | 0.07 |
| Leverage | ||||||
| Debt / Equity | 0.71 | 0.65 | 0.69 | 0.34 | 0.47 | 0.59 |
| Debt / Assets | 0.30 | 0.27 | 0.27 | 0.17 | 0.20 | 0.24 |
| Debt / EBITDA | 4.37 | 3.82 | 8.37 | 0.83 | 1.25 | - |
| Interest coverage | 2.8x | 2.6x | 0.5x | 28.1x | 18.8x | 5.2x |
| Equity multiplier | 2.41 | 2.42 | 2.54 | 2.06 | 2.35 | 2.44 |
| Liabilities / Assets | 0.58 | 0.59 | 0.61 | 0.51 | 0.57 | 0.59 |
| Efficiency | ||||||
| Asset turnover | 0.30 | 0.30 | 0.41 | 0.21 | 0.45 | 0.27 |
| Inventory turnover | 1.51 | 1.65 | 2.45 | 3.82 | 3.40 | 1.08 |
| Days sales outstanding | 69d | 66d | 44d | 96d | 52d | 69d |
| Days inventory outstanding | 242d | 222d | 149d | 95d | 107d | 338d |
| Days payable outstanding | 119d | 115d | 98d | 72d | 66d | 181d |
| Cash conversion cycle | 192d | 172d | 95d | 119d | 93d | 226d |
| Valuation | ||||||
| P / E | 18.3x | 18.8x | 77.8x | 9.4x | 15.3x | 21.5x |
| P / B | 1.6x | 1.7x | 1.8x | 3.1x | 4.4x | 3.3x |
| P / S | 2.3x | 2.4x | 1.8x | 7.1x | 4.1x | 4.9x |
| EV / EBITDA | 14.4x | 13.8x | 30.4x | 8.2x | 12.8x | - |
| Growth | ||||||
| Revenue growth (YoY) | -1.6% | -30.7% | 120.4% | -48.8% | 94.0% | -19.0% |
| Revenue CAGR (3y) | 14.5% | -7.8% | 29.9% | -7.0% | 15.5% | - |
| Revenue CAGR (5y) | 8.3% | 4.2% | 11.7% | - | - | - |
| Gross profit growth (YoY) | 1.6% | -31.5% | 814.7% | -85.5% | 51.9% | -20.0% |
| Operating income growth (YoY) | -6.3% | 658.3% | -97.0% | 42.9% | 224.3% | -57.6% |
| Net income growth (YoY) | -3.2% | 279.0% | -93.2% | 42.7% | 128.6% | -40.9% |
| EPS growth (YoY) | -3.5% | 281.1% | -93.2% | 42.1% | 125.1% | -40.4% |
| EPS CAGR (3y) | -37.1% | -28.5% | -40.0% | 24.0% | 27.2% | -21.4% |
| EPS CAGR (5y) | -4.5% | -13.3% | -27.7% | 9.2% | 26.9% | 9.0% |
| FCF growth (YoY) | -7.7% | 105.2% | -81.6% | -12.8% | 145.8% | 16.7% |
| FCF CAGR (5y) | -5.7% | -1.1% | -19.0% | 12.4% | 16.2% | -1.5% |
| Book value growth (YoY) | -2.0% | -0.9% | -6.9% | 23.9% | 22.1% | 0.2% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$61.20B totalBiopharma Segment$61.20B · 100.0%
Product / service
$170.36B totalExcluding Comirnaty And Paxlovid$54.47B · 32.0%
Product$51.66B · 30.3%
Eliquis$7.96B · 4.7%
Prevnar Prevenar Family$6.49B · 3.8%
Vyndaqel$6.38B · 3.7%
Comirnaty$4.37B · 2.6%
Ibrance$4.12B · 2.4%
Other Hospital$4.03B · 2.4%
Other Primary Care Products$2.86B · 1.7%
Paxlovid$2.36B · 1.4%
Xtandi$2.19B · 1.3%
Padcev$1.94B · 1.1%
Royalty$1.65B · 1.0%
Other Specialty Care$1.59B · 0.9%
Nurtec ODTVydura$1.42B · 0.8%
Pfizer Centre One$1.34B · 0.8%
Oncology Biosimilars$1.30B · 0.8%
Other Oncology Products$1.13B · 0.7%
Xeljanz$1.09B · 0.6%
Abrysvo$1.03B · 0.6%
Lorbrena$1.02B · 0.6%
Inlyta$923.00M · 0.5%
Adcetris$907.00M · 0.5%
Braftovi Mektovi$716.00M · 0.4%
Sulperazon$653.00M · 0.4%
Inflectra Remsima$646.00M · 0.4%
Zavicefta$638.00M · 0.4%
Enbrel$627.00M · 0.4%
Bosulif$611.00M · 0.4%
Tukysa$463.00M · 0.3%
Aromasin$450.00M · 0.3%
Genotropin$446.00M · 0.3%
Orgovyx$421.00M · 0.2%
Octagam$418.00M · 0.2%
Zithromax Zmax$399.00M · 0.2%
Cresemba$349.00M · 0.2%
FSMEIMMUNTico Vac$319.00M · 0.2%
Elrexfio$304.00M · 0.2%
Cibinqo$284.00M · 0.2%
Talzenna$182.00M · 0.1%
Tivdak$147.00M · 0.1%
Pfizer Ignite$41.00M · 0.0%
Geographic
$62.58B totalUS$37.08B · 59.2%
International Developed Markets$16.19B · 25.9%
International Emerging Markets$9.31B · 14.9%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
1.20
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
6/9
Neutral
- ✓Net income positive
- ✓Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- ✗Long-term debt decreased
- ✗Current ratio improved
- ✓No share dilution
- ✓Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing PFIZER INC against the 5 most active filers in the same SIC group.
Dividends
$1.72/share trailing 12 months · +1.2% YoY
| Ex-date | Per share |
|---|---|
| May 8, 2026 | $0.4300 |
| Jan 23, 2026 | $0.4300 |
| Nov 7, 2025 | $0.4300 |
| Jul 25, 2025 | $0.4300 |
| May 9, 2025 | $0.4300 |
| Jan 24, 2025 | $0.4300 |
| Nov 8, 2024 | $0.4200 |
| Jul 26, 2024 | $0.4200 |
| May 9, 2024 | $0.4200 |
| Jan 25, 2024 | $0.4200 |
| Nov 9, 2023 | $0.4100 |
| Jul 27, 2023 | $0.4100 |
| May 11, 2023 | $0.4100 |
| Jan 26, 2023 | $0.4100 |
| Nov 3, 2022 | $0.4000 |
| Jul 28, 2022 | $0.4000 |
| May 12, 2022 | $0.4000 |
| Jan 27, 2022 | $0.4000 |
| Nov 4, 2021 | $0.3900 |
| Jul 29, 2021 | $0.3900 |
| May 6, 2021 | $0.3900 |
| Jan 28, 2021 | $0.3900 |
| Nov 5, 2020 | $0.3605 |
| Jul 30, 2020 | $0.3605 |